Prevalent



PBA affects nearly 2 million people with a variety of underlying neurologic conditionsREF

PBA Symptom Prevalence Estimates From PRISM Registry (n=5290)*REF

Alzheimer's
29%
n=1799
ALS
45%
n=125
MS
46%
n=1215
Parkinson's
26%
n=804
Stroke
38%
n=757
TBI
52%
n=590

*The Center for Neurologic Study-Lability Scale (CNS-LS). The CNS-LS has been validated in patients with MS and ALS. A score ≥13 may suggest PBA symptoms and merits further diagnostic assessment. The PBA estimates in the Avanir-sponsored studies and surveys tend to differ from what has been previously reported in literature. Sampling bias may have occurred given the limited response to the surveys.

PRISM brings greater clarity to the estimated prevalence of PBA symptoms


PRISM reveals 36.7% of patients screened had symptoms suggestive of PBAREF
(CNS-LS ≥13)

  • The largest ever observational study of PBA symptom prevalence was conducted with 5,290 patients enrolled at 173 sites across the USA

  • Assessed the prevalence of PBA symptoms across 6 underlying neurologic conditions in a clinical practice setting

  • Assessed PBA symptoms as measured by CNS-LS scores*

  • Quality of Life impact of neurologic condition and psychotropic medication use were also measured

*The Center for Neurologic Study-Lability Scale (CNS-LS). The CNS-LS has been validated in patients with MS and ALS. A score ≥13 may suggest PBA symptoms and merits further diagnostic assessment.

Please see the PRISM Study Design and Limitations section for more information.


Projected Prevalence of PBA symptoms in a typical 120-bed nursing facilityREF

Neurologic Diagnosis Number of Residents with Neurologic Diagnosis* Projected Number of Residents with PBA Symptoms
Alzheimer’s Disease/Dementia 68 20
Stroke 24 9
Parkinson’s Disease 8 2
TOTAL 100 31
*Centers for Medicaid and Medicare Services Minimum Data Set resident report.
Projection is made utilizing prevalence numbers from PRISM study based on CNS-LS ≥13.

PRISM study design and limitations

Design

Non-interventional PBA registry of at-risk underlying neurologic populations

  • Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson’s disease, stroke, and traumatic brain injury (TBI)

  • Enrolled patients were at least 18 years of age. Patients or caregivers completed the questionnaire

Assessed PBA symptoms as measured by CNS-LS scores

Limitations

  • The CNS-LS was validated as a PBA screening tool in ALS and MS populationsREF

  • A CNS-LS score ≥13 may suggest PBA symptoms and merits further diagnostic assessment

  • The PRISM registry did not evaluate subjects for neuropsychiatric co-morbidities such
    as depression

  • The PRISM registry did not capture therapeutic rationale for use of psychotropic medications

  • The Quality of Life scale did not directly measure the impact of PBA symptoms

  • The statistical analysis plan was not pre-specified


Understanding the Prevalence of PBA Symptoms

click here to download PRISM Reprint. PRISM is the largest observational study to assess PBA symptoms prevalence.REF